New shot could shield breast cancer patients from Chemo's dangerous side effect
NCT ID NCT06711523
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a long-acting injection called PEG-G-CSF to prevent severe neutropenia (dangerously low white blood cell counts) after chemotherapy in 250 women with breast cancer. Participants receive either the test drug or the already-approved Neulasta. The goal is to see if the new injection works as well and is safe, potentially offering another option to reduce infection risk during cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PEG-G-CSF (a long-acting injection to boost white blood cell counts)
What this could lead to
If successful, this could offer a similar option to Neulasta for preventing dangerous drops in white blood cells after chemotherapy, reducing infection risk.
What could go wrong
This is a late-stage trial, but it only includes breast cancer patients on specific chemo regimens. Results may not apply to all cancers or treatments. Side effects like bone pain or allergic reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China